| Unknown | Progesterone and Aminophylline for the Prevention of Preterm Labour Premature Obstetric Labor | Phase 1 | 2017-10-05 |
| Unknown | PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation HIV Infections | — | 2017-09-01 |
| Completed | The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers HIV | Phase 1 | 2017-04-19 |
| Unknown | Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid HIV | Phase 1 | 2016-11-21 |
| Terminated | Pharmacokinetic Effect of Evotaz/Microgynon Co-administration HIV | Phase 1 | 2016-07-01 |
| Suspended | PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers HIV | Phase 1 | 2015-11-01 |
| Completed | SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms HIV | Phase 4 | 2015-11-01 |
| Completed | SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat HIV | Phase 1 | 2015-11-01 |
| Completed | SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over HIV | Phase 4 | 2015-08-04 |
| Completed | SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women HIV | Phase 1 | 2015-08-01 |
| Unknown | SSAT 054: Non Genetic Factors in the Pathogenesis of IBD in Twins Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis | — | 2015-05-01 |
| Unknown | Targeted Clinical Strategies and Low Level Viraemia (LLV) in Boosted Protease Inhibitor Therapy HIV | — | 2015-03-01 |
| Completed | Renal Integrase Study HIV | Phase 4 | 2015-03-01 |
| Unknown | Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity HIV | Phase 4 | 2014-11-01 |
| Completed | SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers HIV | Phase 1 | 2014-10-01 |
| Completed | Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG) HIV | Phase 4 | 2014-04-01 |
| Completed | Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (C HIV | Phase 3 | 2014-01-01 |
| Completed | A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteer HIV | Phase 1 | 2013-04-01 |
| Completed | Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Ril HIV | Phase 1 | 2013-03-01 |
| Completed | A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiret HIV | Phase 4 | 2012-12-01 |
| Completed | A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavi HIV | Phase 4 | 2012-11-01 |
| Completed | A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Ne HIV | Phase 3 | 2012-09-01 |
| Completed | Boceprevir and Ucalm (St John&Apos;s Wort) Hepatitis C | Phase 1 | 2012-08-01 |
| Completed | The Effect of Hyperbilirubinemia on CV Disease, Neurocog Function and Renal Function HIV | — | 2012-01-01 |
| Completed | Atazanavir/Ritonavir and Zinc Pharmacokinetic Study HIV Infection | Phase 4 | 2011-12-01 |
| Completed | Men Who Have Sex With Men (MSM) Neurocog 1&2 Study HIV Related Neurocognitive Impairment | — | 2011-09-01 |
| Unknown | Evolution of Cellular and Viral Resistance in HIV-infected Patients With Lymphoma HIV, Lymphoma | — | 2011-05-01 |
| Completed | The Pharmacology/Aging Clinic HIV Infection | — | 2011-04-01 |
| Completed | Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA. HIV Infection | Phase 1 | 2011-01-01 |
| Withdrawn | Depot Contraception With and Without Lopinavir/Ritonavir HIV Infection | Phase 1 | 2010-12-01 |
| Completed | Atripla to Raltegravir Switch Study for CNS Toxicity HIV Infection | Phase 3 | 2010-10-01 |
| Unknown | Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART) HIV Infection | Phase 1 | 2010-10-01 |
| Completed | PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers HIV Infection, HIV Infections | Phase 1 | 2010-06-01 |
| Completed | Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study HIV, HIV Infections | Phase 1 | 2010-04-01 |
| Terminated | Pre-Exposure Prophylaxis Using TMC278LA HIV Infections | Phase 1 / Phase 2 | 2010-03-01 |
| Completed | PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen HIV Infection | Phase 4 | 2010-01-01 |
| Terminated | Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antige HIV Infections | Phase 4 | 2009-07-01 |
| Completed | Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infe HIV Infections | Phase 1 | 2009-06-01 |
| Terminated | NNRTI/PI Toxicity Switch to Darunavir Study HIV | Phase 4 | 2008-10-01 |
| Completed | Raltegravir and Ezetimibe PK Study HIV | Phase 1 | 2008-06-01 |
| Completed | Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125 HIV | Phase 3 | 2008-06-01 |
| Completed | Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected S HIV | Phase 1 | 2008-05-01 |
| Completed | Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers HIV Infections | Phase 1 | 2008-05-01 |
| Completed | Raltegravir Insulin Sensitivity Study HIV Infections | Phase 1 | 2007-10-01 |
| Completed | Double Protease Inhibitor to Darunavir Switch Study HIV Infections | Phase 4 | 2007-09-01 |
| Completed | TMC 125 Blood Levels Study HIV Infections | Phase 1 | 2007-09-01 |